>중동 및 아프리카 강박 장애(OCD) 약물 시장, 심각도별(경미한 ~ 중간, 중간 ~ 심각한), 하위 유형별(씻기/청소 강박증에 대한 오염 강박증, 확인 강박증에 대한 해악 강박증, 눈에 보이는 강박증이 없는 강박증, 정리, 배열 및 계산 강박증에 대한 대칭 강박증, 쌓아두기, 기타), 약물별(항우울제, 항정신병제, NMDA 차단제, 기타), 투여 경로별(경구, 비경구), 인구 유형별(소아과, 성인), 최종 사용자별(병원, 전문 클리닉, 재택 의료 , 기타), 유통 채널별(병원 약국, 소매 약국, 온라인 약국, 기타), 국가별(남아프리카, 사우디 아라비아, UAE, 이집트, 쿠웨이트, 이스라엘, 중동 및 아프리카의 나머지 지역)입니다.
시장 분석 및 통찰력: 중동 및 아프리카 강박 장애(OCD) 약물 시장
중동 및 아프리카 강박 장애(OCD) 약물 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 8.1%의 CAGR로 성장하고 있으며 2028년까지 2,669만 달러에 도달할 것으로 예상된다고 분석했습니다. 정부의 의료 지원 증가와 현재 및 새로운 OCD 약물 제품에 대한 인식 증가는 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
강박 장애(OCD)는 비합리적이고 통제할 수 없는 생각과 두려움으로 인해 개인이 반복적인 행동을 하게 되는 불안 장애를 말합니다. 강박 장애는 특정 생각이나 두려움에 갇히게 하는 것으로 알려진 장애입니다. 치료 , 요법 및 새로운 치료법의 발전과 항불안제, 항정신병제 및 항우울제의 발전은 OCD 약물 시장에서 다양한 다른 기회를 제공할 것으로 예상됩니다. 그러나 특허 약물의 특허 만료와 브랜드 약물의 제네릭 버전 출시는 예측 기간 동안 시장 성장을 제한할 것으로 예상되는 요인입니다.
OCD 약물 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
중동 및 아프리카 강박 장애(OCD) 약물 시장 범위 및 시장 규모
Obsessive-Compulsive Disorder (OCD) Drugs Market is segmented on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into mild to moderate and moderate to severe. In 2021, the moderate to severe segment is dominating the Middle East, and Africa obsessive obsessive-compulsive disorder (OCD) drugs market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe are predicted to dominate the market.
- On the basis of subtype, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into contamination obsessions with washing/cleaning compulsion, harm obsessions with checking compulsions, obsessions without visible compulsions, symmetry obsessions with ordering, arranging, and counting compulsions, hoarding and others. In 2021, contamination obsessions with washing/cleaning compulsion is are dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to developments in the treatment, therapies, and introduction of novel treatments are predicted to dominate the market.
- On the basis of drugs, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into antidepressants, antipsychotics, NMDA blocker, and others. Antidepressants is further segmented into selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAS), and others. SSRIs is further segmented into fluvoxamine, fluoxetine, paroxetine, sertraline and others. SNRIs is further segmented into duloxetine, venlafaxine and others. TCAS is further segmented into clomipramine, amitriptyline, imipramine and others. Antipsychotics is further segmented into risperidone, haloperidol, quetiapine, olanzapine, aripiprazole and others. NMDA blocker is further segmented into ketamine, memantine, and others. In 2021, the antidepressants segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to advancements in the anti-anxiety, antipsychotic and antidepressant drugs, and the robust pipelines for the development of newer treatment are predicted to dominate the market.
- On the basis of route of administration, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into oral and parenteral. Oral is further segmented into tablets, capsules, and solution. In 2021, the oral segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder (OCD) drugs market due to novel treatment, and advancements in therapies are predicted to dominate the market.
- On the basis of population, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into pediatrics and adults. In 2021, the adults segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to research and development to enhance bioavailability, pharmacology, safety, and dosage parameters is are predicted to dominate the market.
- On the basis of end user, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospitals, specialty clinics, home healthcare and others. In 2021, the hospitals segment is dominating the Middle East and Africa obsessive obsessive-compulsive disorder drug market due to an increase in the cases of prevalence rate of infectious diseases among the population across the globe is predicted to dominate the market.
- On the basis of distribution channel, the Middle East and Africa obsessive compulsive disorder (OCD) drugs market is segmented into hospital pharmacy, retail pharmacy, online pharmacy and others. In 2021, hospital pharmacy segment is dominating the Middle East and Africa obsessive compulsive disorder drug market due to novel treatment and advancements in the anti-anxiety, antipsychotic and antidepressant drugs are predicted to dominate the market.
- In Middle East and Africa, South Africa is the dominant region due to rising demand for effective therapies and rising awareness about the syndrome.
Obsessive-Compulsive Disorder (OCD) Drugs Market Country Level Analysis
The OCD drugs market is analyzed, and market size information is provided on the basis of severity, subtypes, drugs, route of administration, population, end user, and distribution channel.
The countries covered in the OCD market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East & Africa.
Antidepressants segment.in Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of robust pipelines for development of newer treatment and the growth in awareness regarding the disorder.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Strategic initiatives by market players and increasing generic approvals are boosting the market growth of OCD drugs market.
Obsessive-Compulsive Disorder (OCD) Drugs market also provides you with detailed market analysis for every country growth in OCD products industry with drugs sales, impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Laxative Market Share Analysis
OCD drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to OCD drugs market.
The major companies operating in the global obsessive-compulsive disorder (OCD) drugs market are Mallinckrodt, , Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Wockhardt, Lupin Pharmaceuticals, Inc., Amneal Pharmaceuticals LLC., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical industries Ltd., Alvogen, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Par Pharmaceutical, Apotex Inc., Lannett, Abbott, Eli Lilly and Company, Viatria Inc., H. LUNDBECK A/S, GlaxoSmithKline plc., Pfizer Inc., Sebela Pharmaceuticals among others.
Many product launch and agreement are also initiated by the companies’ worldwide, which are also accelerating the OCD drugs market.
For instance,
- In June 2021, Mallinckrodt, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen – dsat) for the treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns).
- 2021년 6월, 혁신 중심의 글로벌 헬스케어 기업인 Zydus Cadila는 오늘 Gilead Sciences Inc.와 Remdesivir의 제조 및 유통을 위한 비독점적 라이선스 계약을 체결했다고 발표했습니다. Remdesivir는 미국 식품의약국(FDA)으로부터 중증 신종 코로나바이러스 증상을 겪는 환자를 치료하기 위한 긴급 사용 허가를 받은 연구 약물입니다. Zydus는 치료제, 백신 및 진단법을 통해 COVID 19와의 싸움을 지원해 왔습니다.
- 2020년 8월, 글로벌 제약 및 생명공학 대기업인 Wockhardt는 영국 정부와 완제 COVID-19 백신을 채우기 위한 계약을 체결했다고 발표했습니다. 제조는 웨일즈 북부 렉섬에 있는 Wockhardt의 자회사인 CP Pharmaceuticals에서 수행됩니다. 계약 조건에 따라 이 회사는 영국 정부가 COVID-19에 맞서 싸우기 위해 여러 백신을 공급할 수 있도록 제조 용량을 예약했습니다. 여기에는 옥스퍼드 대학교와 분사 회사인 Vaccitech가 공동으로 발명하고 AstraZeneca가 라이선스를 받은 백신인 AZD1222가 포함됩니다.
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략은 강박증 약물 시장에서 회사 시장을 강화하고 있으며, 이는 또한 기업이 강박증 약물 제품에 대한 제공을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 SEVERITY LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR OCD DRUGS
6.2 EUROPE REGULATORY FRAMEWORK FOR OCD DRUGS
6.3 AUSTRALIA REGULATORY GUIDANCE ON OCD DRUGS
7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: REIMBURSEMENT SCENARIO
8 COST ANALYSIS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.1.2 INCREASING CASES OF OBSESSIVE-COMPULSIVE DISORDER (OCD) WORLDWIDE
9.1.3 INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS
9.1.4 CHANGES IN LIFESTYLE AND ENVIRONMENTAL STRESS AMONG PEOPLE
9.1.5 INCREASING GENERIC APPROVALS
9.2 RESTRAINTS
9.2.1 RECALL OF DRUGS
9.2.2 ADVERSE EFFECTS OF DRUGS
9.2.3 STRINGENT GOVERNMENT REGULATIONS FOR OCD DRUGS DEVELOPMENT
9.2.4 UNAWARENESS AMONG PEOPLE OF EXISTENCE OF OCD
9.3 OPPORTUNITIES
9.3.1 TECHNOLOGICAL ADVANCEMENT FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
9.3.2 RISING COLLABORATIONS, AND MERGER & ACQUISITIONS AMONG THE MARKET PLAYERS
9.3.3 RISE IN QUALITY CONCERNS
9.4 CHALLENGES
9.4.1 USE OF ALTERNATIVE THERAPIES
9.4.2 LIMITATIONS OF CURRENT OCD TREATMENT
10 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
10.1 IMPACT ON PRICE
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 MARKET BY DRUGS
11.1 TOTAL ADDRESSABLE MARKET
11.2 PATIENT POPULATION (2019-2028)
12 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY
12.1 OVERVIEW
12.2 MODERATE TO SEVERE
12.3 MILD TO MODERATE
13 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE
13.1 OVERVIEW
13.2 CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION
13.3 HARM OBSESSIONS WITH CHECKING COMPULSIONS
13.4 OBSESSIONS WITHOUT VISIBLE COMPULSIONS
13.5 SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS
13.6 HOARDING
13.7 OTHERS
14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS
14.1 OVERVIEW
14.2 ANTIDEPRESSANTS
14.2.1 SELECTIVE SEROTONIN REUPTAKE INHIBITORS
14.2.1.1 FLUVOXAMINE
14.2.1.2 FLUOXETINE
14.2.1.3 PAROXETINE
14.2.1.4 SERTRALINE
14.2.1.5 OTHERS
14.2.2 SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS
14.2.2.1 DULOXETINE
14.2.2.2 VENLAFAXINE
14.2.2.3 OTHERS
14.2.3 TRICYCLIC ANTIDEPRESSANTS
14.2.3.1 CLOMIPRAMINE
14.2.3.2 AMITRIPTYLINE
14.2.3.3 IMIPRAMINE
14.2.3.4 OTHERS
14.3 ANTIPSYCHOTICS
14.3.1 RISPERIDONE
14.3.2 OLANZAPINE
14.3.3 ARIPIPRAZOLE
14.3.4 QUETIAPINE
14.3.5 HALOPERIDOL
14.3.6 OTHERS
14.4 NMDA BLOCKERS
14.4.1 MEMANTINE
14.4.2 KETAMINE
14.4.3 OTHERS
14.5 OTHERS
15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION
15.1 OVERVIEW
15.2 ORAL
15.2.1 TABLET
15.2.2 CAPSULE
15.2.3 SOLUTION
15.3 PARENTERAL
16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION
16.1 OVERVIEW
16.2 ADULTS
16.3 PEDIATRICS
17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 HOME HEALTHCARE
17.5 OTHERS
18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION
19.1 MIDDLE EAST & AFRICA
19.1.1 SOUTH AFRICA
19.1.2 SAUDI ARABIA
19.1.3 UAE
19.1.4 KUWAIT
19.1.5 ISRAEL
19.1.6 EGYPT
19.1.7 REST OF MIDDLE EAST & AFRICA
20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
21 SWOT ANALYSIS
22 COMPANY PROFILE
22.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
22.1.1 COMPANY SNAPSHOT
22.1.2 REVENUE ANALYSIS
22.1.3 COMPANY SHARE ANALYSIS
22.1.4 PRODUCT PORTFOLIO
22.1.5 RECENT DEVELOPMENTS
22.2 H. LUNDBECK A/S
22.2.1 COMPANY SNAPSHOT
22.2.2 REVENUE ANALYSIS
22.2.3 COMPANY SHARE ANALYSIS
22.2.4 PRODUCT PORTFOLIO
22.2.5 RECENT DEVELOPMENTS
22.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
22.3.1 COMPANY SNAPSHOT
22.3.2 REVENUE ANALYSIS
22.3.3 COMPANY SHARE ANALYSIS
22.3.4 PRODUCT PORTFOLIO
22.3.5 RECENT DEVELOPMENTS
22.4 ELI LILLY AND COMPANY
22.4.1 COMPANY SNAPSHOT
22.4.2 REVENUE ANALYSIS
22.4.3 COMPANY SHARE ANALYSIS
22.4.4 PRODUCT PORTFOLIO
22.4.5 RECENT DEVELOPMENTS
22.5 APOTEX INC.
22.5.1 COMPANY SNAPSHOT
22.5.2 COMPANY SHARE ANALYSIS
22.5.3 PRODUCT PORTFOLIO
22.5.4 RECENT DEVELOPMENTS
22.6 VIATRIS INC.
22.6.1 COMPANY SNAPSHOT
22.6.2 REVENUE ANALYSIS
22.6.3 PRODUCT PORTFOLIO
22.6.4 RECENT DEVELOPMENTS
22.7 LANNETT
22.7.1 COMPANY SNAPSHOT
22.7.2 REVENUE ANALYSIS
22.7.3 PRODUCT PORTFOLIO
22.7.4 RECENT DEVELOPMENTS
22.8 GLAXOSMITHKLINE PLC
22.8.1 COMPANY SNAPSHOT
22.8.2 REVENUE ANALYSIS
22.8.3 PRODUCT PORTFOLIO
22.8.4 RECENT DEVELOPMENT
22.9 ALVOGEN
22.9.1 COMPANY SNAPSHOT
22.9.2 PRODUCT PORTFOLIO
22.9.3 RECENT DEVELOPMENTS
22.1 PFIZER INC.
22.10.1 COMPANY SNAPSHOT
22.10.2 REVENUE ANALYSIS
22.10.3 PRODUCT PORTFOLIO
22.10.4 RECENT DEVELOPMENTS
22.11 AMNEAL PHARMACEUTICALS LLC
22.11.1 COMPANY SNAPSHOT
22.11.2 REVENUE ANALYSIS
22.11.3 PRODUCT PORTFOLIO
22.11.4 RECENT DEVELOPMENTS
22.12 DR.REDDY’S LABORATORIES LTD.
22.12.1 COMPANY SNAPSHOT
22.12.2 REVENUE ANALYSIS
22.12.3 PRODUCT PORTFOLIO
22.12.4 RECENT DEVELOPMENTS
22.13 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
22.13.1 COMPANY SNAPSHOT
22.13.2 REVENUE ANALYSIS
22.13.3 PRODUCT PORTFOLIO
22.13.4 RECENT DEVELOPMENTS
22.14 ABBOTT
22.14.1 COMPANY SNAPSHOT
22.14.2 REVENUE ANALYSIS
22.14.3 PRODUCT PORTFOLIO
22.14.4 RECENT DEVELOPMENTS
22.15 LUPIN PHARMACEUTICALS, INC.
22.15.1 COMPANY SNAPSHOT
22.15.2 REVENUE ANALYSIS
22.15.3 PRODUCT PORTFOLIO
22.15.4 RECENT DEVELOPMENTS
22.16 MALLINCKRODT
22.16.1 COMPANY SNAPSHOT
22.16.2 REVENUE ANALYSIS
22.16.3 PRODUCT PORTFOLIO
22.16.4 RECENT DEVELOPMENTS
22.17 PAR PHARMACEUTICAL
22.17.1 COMPANY SNAPSHOT
22.17.2 REVENUE ANALYSIS
22.17.3 PRODUCT PORTFOLIO
22.17.4 RECENT DEVELOPMENTS
22.18 SEBELA PHARMACEUTICALS
22.18.1 COMPANY SNAPSHOT
22.18.2 PRODUCT PORTFOLIO
22.18.3 RECENT DEVELOPMENT
22.19 ZYDUS PHARMACEUTICALS USA INC. (A SUBSIDIARY OF ZYDUS CADILA)
22.19.1 COMPANY SNAPSHOT
22.19.2 REVENUE ANALYSIS
22.19.3 PRODUCT PORTFOLIO
22.19.4 RECENT DEVELOPMENTS
22.2 WOCKHARDT
22.20.1 COMPANY SNAPSHOT
22.20.2 REVENUE ANALYSIS
22.20.3 PRODUCT PORTFOLIO
22.20.4 RECENT DEVELOPMENTS
23 QUESTIONNAIRE
24 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 BELOW MENTIONED ARE THE COST OF OCD DRUGS, AVAILABLE IN DIFFERENT DOSAGE FORMS SUCH AS A TABLET, CAPSULE, PARENTAL, AND STRENGTHS USED MIDDLE EAST AND AFRICALY TO TREAT OBSESSIVE-COMPULSIVE DISORDER.
TABLE 2 DRUGS UNDER INVESTIGATIONS FOR OCD
TABLE 3 R&D COST BY KEY MARKET PLAYERS (USD MILLIONS) (2020)
TABLE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA MILD TO MODERATE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUB TYPE 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA CONTAMINATION OBSESSIONS WITH WASHING/CLEANING COMPULSION IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA HARM OBSESSIONS WITH CHECKING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA OBSESSIONS WITHOUT VISIBLE COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA SYMMETRY OBSESSIONS WITH ORDERING, ARRANGING, AND COUNTING COMPULSIONS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA HOARDING IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TRICYCLIC ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA ADULTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA PEDIATRICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN OBSESSIVE-COMPULSIVE (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 57 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 58 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 59 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 60 SOUTH AFRICA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 85 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 86 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 87 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 88 UAE ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 89 UAE SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 90 UAE SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 91 UAE TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 92 UAE ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 93 UAE NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 94 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 95 UAE ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 97 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 98 UAE OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 99 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 100 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 101 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 102 KUWAIT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 103 KUWAIT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 104 KUWAIT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 105 KUWAIT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 106 KUWAIT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 107 KUWAIT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 108 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 KUWAIT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 111 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 112 KUWAIT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
TABLE 128 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SUBTYPE, 2019-2028 (USD MILLION)
TABLE 129 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 130 EGYPT ANTIDEPRESSANTS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 131 EGYPT SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 132 EGYPT SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT TRICYCLIC ANTIDEPRESSANTS (TCAS) IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 134 EGYPT ANTIPSYCHOTICS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT NMDA BLOCKERS IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DRUGS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ORAL IN OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 138 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 140 EGYPT OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 141 REST OF MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET SEGMENTATION
FIGURE 11 RISE IN CLINICAL TRIALS FOR OBSESSIVE-COMPULSIVE DISORDER AND INCREASING R&D INVESTMENT BY KEY MARKET PLAYERS ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 SEVERITY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUG MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES ABD CHALLENGES OF MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET
FIGURE 14 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020
FIGURE 15 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, 2020-2028 (USD MILLION)
FIGURE 16 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY, CAGR (2021-2028)
FIGURE 17 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DIOSRDER (OCD) DRUG MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020
FIGURE 19 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, 2020-2028 (USD MILLION)
FIGURE 20 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, CAGR (2020-2028)
FIGURE 21 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SUBTYPE, LIFELINE CURVE
FIGURE 22 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020
FIGURE 23 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, 2020-2028 (USD MILLION)
FIGURE 24 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, CAGR (2020-2028)
FIGURE 25 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DRUGS, LIFELINE CURVE
FIGURE 26 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 29 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020
FIGURE 31 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, 2020-2028 (USD MILLION)
FIGURE 32 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY POPULATION, CAGR (2021-2028)
FIGURE 33 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY, LIFELINE CURVE
FIGURE 34 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020
FIGURE 35 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 36 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, CAGR (2021-2028)
FIGURE 37 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 39 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 40 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 41 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: SNAPSHOT (2020)
FIGURE 43 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020)
FIGURE 44 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2021 & 2028)
FIGURE 45 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY COUNTRY (2020 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: BY SEVERITY (2021 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA OBSESSIVE-COMPULSIVE DISORDER (OCD) DRUG MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
